再生元制药公司（Regeneron Pharmaceuticals）旗下药物Dupixent®（度普利尤单抗）在针对嗜酸性粒细胞性食管炎（EoE）的四期临床试验中取得积极进展。最新数据显示，该药物能显著改善患者的食管功能指标，为这一难治性疾病的治疗提供了新的临床证据。
试验结果表明，Dupixent治疗组在食管黏膜组织学评分、吞咽困难症状量表等关键终点上均表现出统计学意义的改善。这一发现进一步验证了度普利尤单抗通过抑制IL-4和IL-13信号通路对EoE病理机制的干预作用。
作为全球首个获批用于EoE的生物制剂，Dupixent此次四期试验数据将为其在真实世界的临床应用提供更充分的循证支持。研究人员指出，食管功能改善直接关联患者的生活质量提升，这对慢性炎症性食管疾病的管理具有重要意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.